Pharmacyclics, the maker of lymphoma and leukemia drug Imbruvica, has just released positive news regarding its latest trial for the drug. Shares of the pharmaceutical company were halted before the release and then ended the trading day up by 0.67% to close at $256.70 per share.
Earlier this month, AbbVie reportedly made an offer of $261.25 per share in cash and stock to acquire Pharmacyclics.
Also read: Huntsman, Clariant Near Deal to Merge
16:15 Who's in charge of outer space?24